David Klonoff, MD
Volunteer Clinical Professor
Medicine
School of Medicine

415-353-2350

David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology. He is Medical Director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California and a Clinical Professor of Medicine at UCSF. Dr. Klonoff received the American Diabetes Association’s 2019 Outstanding Physician Clinician Award.

Show full bio (660 words) Hide full bio

He received an FDA Director’s Special Citation Award in 2010 for outstanding contributions related to diabetes technology. In 2012 Dr. Klonoff was elected as a Fellow of the American Institute of Medical and Biological Engineering (AIMBE) and cited as among the top 2% of the world’s bioengineers for his engineering work in diabetes technology. He received the 2012 Gold Medal Oration and Distinguished Scientist Award from the Dr. Mohan’s Diabetes Specialities Centre and Madras Diabetes Research Foundation of Chennai, India. In 2022 he was the first physician to ever receive the Institute of Electrical and Electronics Engineering (IEEE) Conformity Assessment Award. Dr. Klonoff was invited to speak to the US Congressional Diabetes Caucus in 2017, participate in the White House Health and Cybersecurity Roundtable in 2015, and speak at the European Parliament in 2010. He is the Founding Editor-in-Chief of Journal of Diabetes Science and Technology. He has authored over 360 publications in PubMed journals including four of the first ten articles on diabetes device cybersecurity. His h-index is 65. Dr. Klonoff has been a Principal Investigator on over 120 clinical trials of diabetes drugs and devices. He was the lead investigator for the first randomized controlled multicenter trial of an outpatient artificial pancreas product by Medtronic, whose results were published in the New England Journal of Medicine. He chaired the scientific advisory board for the first FDA-cleared insulin patch pump and participated in developing the first FDA-cleared dedicated diabetes telemedicine system. Dr. Klonoff coined the term “diabetes technology” and founded the Diabetes Technology Meeting and the Hospital Diabetes Meeting. He is senior editor of the world's first three books about diabetes digital health and senior author of the first publication in PubMed about diabetes and ChatGPT. He published the first article that in COVID-19, correcting the hyperglycemia of diabetes increases recovery. He is a co-author of the 2023 ADA/EASD/JBDS/AACE/DTS article on "Hyperglycemic Crises in Adult Patients with Diabetes". Dr. Klonoff has chaired or served on 62 grant review panels including for NIH, CDC, NASA, NSF, US Army, NOAA, ADA, and JDRF; plus agencies in 12 foreign countries. He is Chair of the Scientific Advisory Board of the TexasA&M/UCLA/FIU/Rice PATHS-UP Engineering Research Center and a member of the Scientific Advisory Board of the Singapore General Hospital Diabetes Clinic of the Future. Dr. Klonoff is Medical Director of the DIabetes Research Hub. He chaired the first and second CLSI POCT05 Performance Metrics for Continuous Interstitial Glucose Monitoring Panel, the Continuous Glucose Monitors and Automated Insulin Dosing Systems in the Hospital Consensus Guideline Panel, and the Continuous Ketone Monitoring Consensus Panel. He was co-Chair of the Integration of Continuous Glucose Monitor Data into the EHR (iCoDE) standard for automatic uploading of wearable device data into the EHR and is now co-Chair of iCoDE2 for integrating insulin dosing data from connected devices into the EHR. He chaired the SC-award winning IEEE 2621 Standards for Wireless Diabetes Device Security Assurance Committee (whose standard was recognized by FDA in 2022 on its scientific and technical merit) and the IEEE 2621 Conformity Assessment Committee, as well as DTSec and DTMoSt, which were the world’s 1st and 2nd consensus medical device cybersecurity standards. For this work Dr. Klonoff was featured in an article in Wired Magazine. Dr. Klonoff is a graduate of UC Berkeley, where he was elected to Phi Beta Kappa in his junior year, and UCSF Medical School, where he was elected to Alpha Omega Alpha in his junior year. His postgraduate training included two years at UCLA Hospital and three years at UCSF Hospitals.

PRESENT ACADEMIC AND PROFESSIONAL POSITION 2006-Present Editor-in-Chief, Journal of Diabetes Science and Technology 2000-Present Medical Director, Dorothy L. and James E. Frank Diabetes Research Institute, Mills-Peninsula Medical Center, San Mateo, California 1995-Present Clinical Professor, Department of Medicine, U.C. San Francisco EDUCATION 1972-1976 University of California at San Francisco: M.D. 1968-1972 University of California at Berkeley: B.S. in Genetics (with Highest Honors)

Awards

Show all (10) Hide

  • Conformity Assessment Award, Institute of Electrical and Electronics Engineering (IEEE) Standards Association, 2022
  • Outstanding Physician-Clinician in Diabetes Award, American Diabetes Association, 2019
  • Visiting Professor, Tokyo University of Agriculture and Technology, Graduate School of Engineering, 2016
  • FRCP (Edin), Fellow of Royal College of Physicians of Edinburgh, 2014
  • Fellow AIMBE, American Institute of Medical and Biological Engineering, 2013
  • Gold Medal Oration Award, Madras (India) Diabetes Research Foundation, 2012
  • Director's Citation, FDA, 2010
  • FACP, American College of Physicians, 1991
  • Alpha Omega Alpha (Junior Year), UC San Francisco, 1975
  • Phi Beta Kappa (Junior Year), UC Berkeley, 1971

Education & Training

Show all (5) Hide

  • BS Genetics UC Berkeley
  • Resident Internal Medicine UC San Francisco
  • Endocrinology Fellow Metabolic Research Unit UC San Francisco
  • MD School of Medicine UC San Francisco
  • Intern and Resident Internal Medicine UCLA Hospital

Interests

Show all (6) Hide

  • Bioengineering
  • Clinical pharmacology
  • Digital health
  • Diabetes
  • Diabetes technology
  • Cybersecurity

Websites

Show all (13) Hide

Publications (365)

Top publication keywords:
Insulin Infusion SystemsBlood Glucose Self-MonitoringHyperglycemiaDiabetes Mellitus, Type 1HypoglycemiaEquipment and SuppliesComputer SecurityDiabetes MellitusPancreas, ArtificialInsulinHypoglycemic AgentsDiabetes Mellitus, Type 2Injections, SubcutaneousBlood GlucoseMonitoring, Physiologic

Show all (360 more) Hide